Literature DB >> 21628326

FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model.

Tobias G Schips1, Astrid Wietelmann, Katharina Höhn, Silvia Schimanski, Paul Walther, Thomas Braun, Thomas Wirth, Harald J Maier.   

Abstract

AIMS: The transcription factor FoxO3 contributes to anti-hypertrophic signalling in the heart presumably by regulating autophagic-lysosomal and ubiquitin-proteasomal pathways. We wanted to study FoxO3 function in the adult heart in vivo by expressing a constitutively active mutant of FoxO3 in transgenic mice. METHODS AND
RESULTS: We generated transgenic mice in which a tetracycline-regulated constitutively active FoxO3 transgene (FoxO3-CA) is controlled by the heart-specific α-myosin heavy chain promoter. Cardiac-specific expression in adult mice resulted in a decrease in heart weight by 25% and a reduction in stroke volume and cardiac output. The decrease in heart size was due to a reduction in the size of individual cardiomyocytes, whereas there was no evidence for increased cell death. FoxO3 activation was accompanied by the initiation of a foetal gene programme with increased expression of β-myosin heavy chain and natriuretic peptides, and by the activation of AKT and mammalian target of rapamycin signalling. As shown by electron microscopy, FoxO3-CA massively stimulated destruction of sarcomeres and autophagy, and induced expression of LC3-II and BNIP3. When FoxO3-CA expression was shut off in affected mice, cardiac atrophy and dysfunction as well as molecular markers were normalized within 1 month. FoxO3-CA expression did not counteract hypertrophy induced by transverse aortic constriction.
CONCLUSION: Heart-specific expression of constitutively active FoxO3 leads to reversible heart atrophy. The reversibility of the phenotype suggests a remarkable ability of the adult myocardium to respond to different regulatory cues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628326     DOI: 10.1093/cvr/cvr144

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  51 in total

Review 1.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 2.  The return of the nucleus: transcriptional and epigenetic control of autophagy.

Authors:  Jens Füllgrabe; Daniel J Klionsky; Bertrand Joseph
Journal:  Nat Rev Mol Cell Biol       Date:  2013-12-11       Impact factor: 94.444

3.  FoxO3 hastens autophagy and shrinks the heart but does not curtail pathological hypertrophy in adult mice.

Authors:  Xuejun Wang; Huabo Su
Journal:  Cardiovasc Res       Date:  2011-07-08       Impact factor: 10.787

4.  Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1.

Authors:  Peng Xia; Jingrui Chen; Yuening Liu; Maya Fletcher; Brian C Jensen; Zhaokang Cheng
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

5.  DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress.

Authors:  Bridget Simonson; Vinita Subramanya; Mun Chun Chan; Aifeng Zhang; Hannabeth Franchino; Filomena Ottaviano; Manoj K Mishra; Ashley C Knight; Danielle Hunt; Ionita Ghiran; Tejvir S Khurana; Maria I Kontaridis; Anthony Rosenzweig; Saumya Das
Journal:  Sci Signal       Date:  2017-02-28       Impact factor: 8.192

Review 6.  Regulation of autophagy by metabolic and stress signaling pathways in the heart.

Authors:  Youngil Lee; Hwa-Youn Lee; Asa B Gustafsson
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

7.  Serine 574 phosphorylation alters transcriptional programming of FOXO3 by selectively enhancing apoptotic gene expression.

Authors:  Z Li; J Zhao; I Tikhanovich; S Kuravi; J Helzberg; K Dorko; B Roberts; S Kumer; S A Weinman
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

8.  A Novel Collagen Matricryptin Reduces Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and Angiogenesis.

Authors:  Merry L Lindsey; Rugmani Padmanabhan Iyer; Rogelio Zamilpa; Andriy Yabluchanskiy; Kristine Y DeLeon-Pennell; Michael E Hall; Abdullah Kaplan; Fouad A Zouein; Dustin Bratton; Elizabeth R Flynn; Presley L Cannon; Yuan Tian; Yu-Fang Jin; Richard A Lange; Dorota Tokmina-Roszyk; Gregg B Fields; Lisandra E de Castro Brás
Journal:  J Am Coll Cardiol       Date:  2015-09-22       Impact factor: 24.094

Review 9.  Posttranslational modification and quality control.

Authors:  Xuejun Wang; J Scott Pattison; Huabo Su
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

Review 10.  FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.